Scientists create new tool for identifying powerful HIV antibodies

May 9, 2013, NIH/National Institute of Allergy and Infectious Diseases

A team of NIH scientists has developed a new tool to identify broadly neutralizing antibodies (bNAbs) capable of preventing infection by the majority of HIV strains found around the globe, an advance that could help speed HIV vaccine research.

Scientists have long studied HIV-infected individuals whose blood shows powerful neutralization activity because understanding how HIV bNAbs develop and attack the virus can yield clues for HIV vaccine design. But until now, available methods for analyzing did not easily yield specific information about the HIV bNAbs present or the parts of the virus they targeted. In addition, determining where and how HIV bNAbs bind to the virus has been a laborious process involving several complicated techniques and relatively large quantities of blood from individual donors.

The new tool lets scientists determine precisely the HIV bNAbs present in a particular blood sample by analyzing the neutralized there. Called neutralization fingerprinting, the tool is a (a problem-solving procedure) that exploits the large body of data on HIV bNAbs generated in recent years. The neutralization fingerprint of an is a measurement of which it can block and with what intensity. Antibodies that target the same portion of the virus tend to have similar fingerprints.

Blood samples contain mixtures of antibodies, so the new algorithm calculates the specific types of HIV bNAbs present and the proportion of each by comparing the blood's neutralization data with the fingerprints of known HIV bNAbs. This approach is particularly useful when other methods of determining bNAbs targets in a blood sample are not feasible, such as when just a small amount of blood is available. Neutralization fingerprinting also is significantly faster than older analytic methods. According to the researchers who developed the assay, the underlying approach could be applied to the study of human responses to other pathogens, such as influenza and hepatitis C viruses, for which scientists have much information about .

Explore further: HIV antibodies that are worth the wait

More information: I. Georgiev et al. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization. Science DOI: 10.1126/science.1233989 (2013).

Related Stories

HIV antibodies that are worth the wait

March 28, 2013
An effective vaccine against HIV-1 remains elusive, but one promising strategy focuses on designer antibodies that have much broader potency than most normal, exquisitely specific antibodies. These broadly neutralizing antibodies ...

Knowing origin of broadly neutralizing antibodies could aid universal flu vaccine design

August 29, 2012
National Institutes of Health scientists have identified how a kind of immature immune cell responds to a part of influenza virus and have traced the path those cells take to generate antibodies that can neutralize a wide ...

Researchers isolate new potent and broadly effective antibodies against HIV

August 17, 2011
A team of researchers at and associated with the International AIDS Vaccine Initiative (IAVI), The Scripps Research Institute, the biotechnology company Theraclone Sciences and Monogram Biosciences Inc., a LabCorp company, ...

Researchers discuss challenges to developing broadly protective HIV vaccines

September 7, 2011
The human body can produce powerful antibodies that shield cells in the laboratory against infection by an array of HIV strains. In people, however, recent research shows that these broadly neutralizing antibodies are not ...

Team develops mathematical model to measure hidden HIV

May 8, 2013
(Medical Xpress)—Scientists have long believed that measuring the amount of HIV in a person's blood is an indicator of whether the virus is actively reproducing. A University of Delaware-led research team reports new evidence ...

Recommended for you

HIV-1 genetic diversity is higher in vaginal tract than in blood during early infection

January 18, 2018
A first-of-its-kind study has found that the genetic diversity of human immunodeficiency virus type 1 (HIV-1) is higher in the vaginal tract than in the blood stream during early infection. This finding, published in PLOS ...

War in Ukraine has escalated HIV spread in the country: study

January 15, 2018
Conflict in Ukraine has increased the risk of HIV outbreaks throughout the country as displaced HIV-infected people move from war-affected regions to areas with higher risk of transmission, according to analysis by scientists.

Researchers offer new model for uncovering true HIV mortality rates in Zambia

January 12, 2018
A new study that seeks to better ascertain HIV mortality rates in Zambia could provide a model for improved national and regional surveillance approaches, and ultimately, more effective HIV treatment strategies.

New drug capsule may allow weekly HIV treatment

January 9, 2018
Researchers at MIT and Brigham and Women's Hospital have developed a capsule that can deliver a week's worth of HIV drugs in a single dose. This advance could make it much easier for patients to adhere to the strict schedule ...

New long-acting, less-toxic HIV drug suppresses virus in humanized mice

January 8, 2018
A team of Yale researchers tested a new chemical compound that suppresses HIV, protects immune cells, and remains effective for weeks with a single dose. In animal experiments, the compound proved to be a promising new candidate ...

Usage remains low for pill that can prevent HIV infection

January 8, 2018
From gritty neighborhoods in New York and Los Angeles to clinics in Kenya and Brazil, health workers are trying to popularize a pill that has proven highly effective in preventing HIV but which—in their view—remains woefully ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.